FDA Clears Opus Genetics’ IND Application For Opgx-RDH12, Investigational Gene Therapy For Treatment Of RDH12-Associated Leber Congenital Amaurosis

Loading news article.

FDA Clears Opus Genetics’ IND Application For Opgx-RDH12, Investigational Gene Therapy For Treatment Of RDH12-Associated Leber Congenital Amaurosis | WAPE

FDA Clears Opus Genetics’ IND Application For Opgx-RDH12, Investigational Gene Therapy For Treatment Of RDH12-Associated Leber Congenital Amaurosis

Article summary

Related companies

Analyzed by WAPE AI.

Comments —